|
Accueil > Actualité
Sanofi: positive data in RSV in infants
(CercleFinance.com) - Sanofi reports new positive data from the HARMONIE Phase IIIb clinical trial, confirming that its nirsevimab prevents hospitalisations of infants due to RSV with high and consistent efficacy.
They show an 83.21% reduction in hospitalisations for lower respiratory tract infections in infants under 12 months of age who received a single dose of nirsevimab compared to those who received no preventive treatment. Over 8,000 infants were included in the study, which took place in France, Germany and the UK. The data was presented at the 41st Annual Congress of the European Society for Paediatric Infectious Diseases (ESPID). Copyright (c) 2023 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
